Neuroendocrinology Letters ISSN 0172-780X - 2017
Editor-in-Chief: Peter G. Fedor-Freybergh
Neuroendocrinology Letters is an international, peer-reviewed transdisciplinary journal covering the fields of Neurosciences, Neurophysiology, Neuroendocrinology, Psychoneuroimmunology, Neuropsychopharmacology, Reproductive Medicine, Chronobiology, Human Ethology and related areas for RAPID publication of Original Papers, Review Articles, Clinical Reports, and other contributions from all the fields covered by Neuroendocrinology Letters.
AIM & SCOPE
Papers from both basic research and clinical research (methodology, molecular and cellular biology, anatomy, histology, biology, embryology, teratology, normal and pathological physiology, biophysics, pharmacology, pathology and experimental pathology, biochemistry, neurochemistry, neuropsychopharmacology, enzymology, human ethology, chronobiology, receptor studies, endocrinology, immunology and neuroimmunology, animal physiology, animal breeding and ethology, psychology and others) will be considered.
The Journal publishes original papers and review articles. Brief reports, special communications, proved they are based on adequate experimental evidence, clinical studies, case reports, commentaries, discussions, letters to the editor (correspondence column), book reviews, congress reports and other categories of articles (philosophy, art, social issues, medical and health policies, biomedical history, etc.) will be taken under consideration.
The requirements for publishing in NEURO-ENDOCRINOLOGY LETTERS are in accordance with the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals.” 5th edition. JAMA 1997; 277: 927–934.
FAST TRACK PUBLICATION
The Neuroendocrinology Letters can publish high-priority papers 2–4 weeks after acceptance. A fast-tracked manuscript will be posted on our website (www.nel.edu) earlier than it appears in the printed journal, as well as sent to Medline ahead of publication.
SUBMISSION OF PAPERS
Material submitted to the Journal must have not been published previously in printed or electronic format and is not under consideration by another publication or electronic medium.
Quality of science, originality and quality of presentation belong to the basic evaluation criteria during review process. The authors are invited to submit a Press Release together with submission, underlining the novelty and originality of their research.
All manuscripts submitted for publication should be written in clear, plain English (American or British English spelling), and APPROVED by a native English speaker in case that the correspondent author is not. The papers with insufficient English language will be rejected by the Editor-in-Chief immediately after submission, and will be returned to the author without further processing.
All authors must give a signed consent for publication in a letter submitted with the manuscript.
CONFLICT OF INTEREST STATEMENT:
DISCLOSURE OF BIOMEDICAL FINANCIAL INTERESTS AND POTENTIAL CONFLICTS OF INTEREST.
Authors of research articles should disclose any financial arrangement they may have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product.
Journal policy requires that reviewers, associate editors, editors, and senior editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.
Financial Disclosure (select relevant items), sign, scan and send with submission.
☐ (A) I certify that all my affiliations (relationships) with or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties) with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript are completely disclosed below or in an attachment (or separate sheet).
☐ (B) I certify that all financial and material support for this research and work are clearly identified in the manuscript and financial relationships are separated into those relevant to the subject matter or materials discussed in this manuscript and all professional financial relationships during the period from inception of the work until its publication are revealed (Acknowledgement section).
☐ (C) I have no financial interests in this manuscript and no affiliations (relationships) to disclose.
Each author must read and sign the statement on financial disclosure. If necessary, photocopy this document to distribute to coauthors for their signatures. Please return all copies to Neuroendocrinology Letters by email together with the submission.
PUBLICATION FEES - see Authors/publication-fees
LENGTH OF PAPERS / MANUSCRIPT PAGES
No limitations to the total length of their paper, independently of the category (Original papers, Review papers, Clinical Reports, Case Reports, etc.) will be applied. Manuscripts should be typed double-spaced on numbered pages and conform to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals.” Two manuscript pages is approximately one printed page.
REVIEWING
All submitted manuscripts are reviewed initially by the Editor-in-Chief. Those manuscripts with insufficient priority for publication are rejected promptly. Other manuscripts are sent to relevant senior scientists for RAPID peer review. The identities of both peer-reviewers and authors are kept confidential. The comments by the reviewers may be conveyed to the authors by the Editor, at his discretion.
Manuscripts are reviewed with due respect for the author’s confidentiality. At the same time, reviewers also have rights to confidentiality, which are respected by the editor. The editor ensures both the authors and the reviewers that the manuscripts sent for review are privileged communications and private intellectual property of the author.
The final decision for Acceptance of Refusal is always up to Editor-in-Chief.
When submitting a manuscript for consideration for publication, authors are strongly encouraged to suggest the names of potential reviewers of their choice.
If an author for any reason wishes to withdraw his/her submitted manuscript from publication, the editor will always respect this wish unless the submitted and accepted manuscript has already passed publishing procedures. The reason for withdrawal should be clearly defined (double submission, double publication, serious flaw in experiments outlined in the submitted article, or else). A request for withdrawal is usually processed within 3 weeks. A separate Letter from the Editor-in-Chief will be sent to the authors for their reference.
AUTHORITY & RESPONSIBILITY
The intellectual content of the paper is the responsibility of the authors. The Editors and the Publisher accept no responsibility for the opinions and statements of the authors. While every effort will be made by the Editors and the Publisher to avoid inaccurate and misleading data, they accept no liability whatsoever for the consequence of inaccurate information. The authors undertake to keep the Editor and the Publisher fully and effectually indemnified against any liability of claims that may arise from the publication of inaccurate and/or misleading data.
COPYRIGHT
It is a condition of publication that the authors transfer the world copyright of their manuscripts to the Neuroendocrinology Letters. All manuscripts should therefore be accompanied by a signed statement that the article is original, is not under consideration or has not been previously published in another journal. Nevertheless, authors will be entitled to publish any part of their paper elsewhere without permission, providing the usual acknowledgments and reference to the ORIGINAL source. Authors will be notified if a request to publish a part or whole of their paper is received. Illustrations, figures, tables or quotations from other publications are already copyrighted and can be reproduced only with written permission from the copyright owner. Written permission to use these should accompany the manuscript upon submission.
ETHICS
The Editors and the Publisher expect that the authors of papers will have obtained ethical consent and followed those legal and regulatory requirements for human experimentation with drugs, including informed consent, according to procedures which apply in their institution and country. When reporting experiments on animals, indicate whether the institution’s or a national research council’s guide for, or any national law on, the care and use of laboratory animals was followed.
PRESENTATION
Manuscripts should be typed on numbered pages and conform to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” except the Reference section (see below).
The pages should be numbered consecutively, beginning with the Title page. The sections of the manuscript should be in following sequence: Title page, Abstract (structured for Original papers and non-structured for Review Articles), Key words, Abbreviations, Main text (Introduction, Material and methods, Results and Discussion), Acknowledgments, References, Tables and Figures. Particular attention should be taken to ensure that the manuscript adheres to the Instructions for Authors of the Neuroendocrinology Letters in all respects. The use of footnotes is not permitted (numbered comments/footnotes can be added at the end of the main text, before the Reference section).
It is very important that all the text is typed without extra spaces between words and that all text within a paragraph is typed without extra carriage returns between the lines. To make a new paragraph, only a carriage return is allowed (tabs allowed for numbered or bullet lists). For tables, see TABLES.
The Editors reserve the right to alter manuscripts whenever necessary to make them conform to the stylistic and bibliographic conventions of the Neuroendocrinology Letters.
COVER LETTER
To be sent together with submission to the Editor-in-Chief of Neuroendocrinology Letters. Briefly describe the main outcome and the originality of your research.
PRESS RELEASE - Optional. Aimed for the interested parties and laymen, short description of your findings, including the novelty and originality.
TITLE PAGE
- The title itself.
- The name(s) of the author(s): (s) First name + Family name and highest academic degree.
- Author’s Affiliations: The name(s) of the department(s) or institution(s) from which the study originated.
- Corresponding Author: The name and full address, including telephone and fax numbers, e-mail address(es) and other useful information of the corresponding author. The authors are obliged to inform the publisher immediately about any change of their fax, telephone, e-mail and ordinary mail address.
- A “running headline,” a maximum of 40 characters, including word spaces.
ABSTRACT and KEY WORDS
A structured abstract (Original Articles) and non-structured abstract (Review papers) not exceeding 250 words should state what was done, including OBJECTIVES, DESIGN, MATERIAL AND METHODS, RESULTS, the main findings, CONCLUSION, and how the work was interpreted. Additional headings may be used.
At least 5 to 10 key words should be used, which correspond to MESH headings by Medline. The key words should be separated by semicolons. The key words will be included in the Subject Index of the volume.
ACKNOWLEDGMENTS
The scientific and material contributions of others to the work should be acknowledged. Any grant supports should be listed and permission for reproduction of published material acknowledged. Authors are responsible for obtaining written permission from anyone acknowledged by name. The acknowledgments will be published as an appendix to the text.
ABBREVIATIONS & UNITS
List of abbreviations and symbols used and spell them out in full. Abbreviations and symbols must be standard, and SI units (The International System of Units) should be used throughout. Drugs should be described by their official names, but trade names should be indicated in brackets the first time a drug is quoted in the main text.
MAIN TEXT
The text is conventionally divided into sections headed: Introduction, Material and methods, Results and Discussion. Lengthy papers may require subheadings for clarification.
INTRODUCTION
State clearly the purpose of the paper. Do not review the subject extensively and give only pertinent references.
MATERIAL & METHODS
Describe your selection of the observational subjects (patients or laboratory animals, including controls) clearly. Describe the study population in detail. Identify the methods and procedures in sufficient detail to allow other workers to reproduce the results. If the methods used are new or substantially modified, describe them and state their limitations.
When reporting research on human beings, the authors must include an assurance that the work was approved by a medical ethics committee and that the subjects gave their informed consent to participate. (See Ethics.)
When reporting experiments on animals, indicate whether the institution’s or a national research council’s guide for, or any national law on, the care and use of laboratory animals was followed. (See Ethics.)
RESULTS
Do not repeat in the text all the data displayed in the tables or illustrations; only important observations should be emphasized or summarized.
DISCUSSION
Emphasize only the new and important aspects and conclusions of the study, including the implications and the limitations of the findings and their relation to other relevant studies. The conclusions should be clearly linked with the objectives of the study. Avoid unqualified statements and conclusions that are not supported by the data. Do not claim priority, and do not allude to work in progress. State new hypotheses when warranted, but clearly label them as such. Recommendations, when appropriate, may be included.
STATISTICS
Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported details. The design of the study and the data sources should be clearly identified. The statistical methods used should be described so that it is clear which method was used and where. Give relevant references and additional details if nonstandard methods or analyses have been applied. The basic principle is to supply sufficient information about design and analysis to allow the research to be repeated by someone else. The presentation of the analysis should include relevant summaries of the data, not just the results of significance testing. The use of confidence interval is encouraged.
REFERENCES - NEL EndNote file .ens
Responsibility for the accuracy of bibliographic citations lies entirely with the authors. Citations in the text: Every reference cited in the main text must be present in the reference list, and vice versa.
All citations IN THE MAIN TEXT should refer to:
- Single author: (Norton, 2000)
the author’s name (without initials, unless there is ambiguity) and the year of publication; - Two authors: (Krusz & Stillman, 2001)
- Three or more authors: (Edwards et al. 2001)
Citations may be made directly (or parenthetically).
Groups of references should be listed first alphabetically, then chronologically.
Example: “reports and open studies are available (Norton, 2000; Edwards et al. 2001; Krusz & Stillman, 2001). Mathew et al. (2000) used a fixed and relatively low dosage of valproate and accomplished …”
REFERENCE LIST
The Neuroendocrinology letter uses the AMA citation style. Please ensure that you have correctly cited all the references according to AMA style: https://www.lib.jmu.edu/citation/amaguide.pdf
Find the examples of correct AMA style citations below:
1. Standard journal article: List all authors when six or less. When seven or more, list only the first six and add et al. Example: Parkin DM, Clayton D, Black RJ, Masuyer E, Friedl HP, Ivanov E, et al (1996). Childhood leukemia in Europe after Chernobyl: 5 year follow-up. Br J Cancer. 73: 1006–1012.
If the language is not English, add the translated title in brackets, e.g. Swedin G (1979). Transkutan elektrisk nervstimulering som smärtlindring vid förlossning. [(Transcutaneous electrical nerve stimulation for analgesia in childbirth.) (In Swedish with English abstract.)] Läkartidningen. 776: 1946–1948.
2. Books and other monographs
a) Personal author(s): Ringsven MK, Bond D (1996). Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar Publishers.
b) Editor(s) as author(s): Norman IJ, Redfern SJ, editors (1996). Mental healthcare for elderly people. New York: Churchill Livingstone.
c) Chapter in a book: Phillips SJ, Whisnant JP (1995). Hypertension and stroke. In: Laragh J Brenner BM, editors. Hypertension: pathophysiology, diagnosis, management. 2nd ed. New York: Raven Press. p. 465–478.
d) Conference proceedings: Kimura J, Shibasaki H, editors (1996). Recent advances in clinical neurophysiology. Proceedings of the 10th International Congress of EM and Clinical Neurophysiology; Oct 15–19, 1995; Kyoto, Japan. Amsterdam: Elsevier.
e) Conference paper: Bengtsson S, Solheim BG (1992). Enforcement of data protection, privacy and security in med ical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, editors. MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics; Sept 6–10, 1992; Geneva, Switzerland. Amsterdam: North-Holland. p. 1561–155.
f) Dissertation: Kaplan SJ (1995). Post-hospital home health care: the elderly’s access and utilization (dissertation). St. Louis (MO): Washington Univ.
TABLES AND FIGURES
Tables and Figures should be numbered consecutively and provided with a title and legend. Enough detail should be given in the Figure Legends to understand the Figure content, so that the reader does not have to it look up within the main text.
Be sure that each table and figure is cited in the main text (Table 3, Figure 3).
Figures, illustrations, photographs, representational drawings, graphs, etc. must be high quality (.tiff, .eps or .jpg in high resolution, original Illustrator file .ai or PowerPoint file) must be professionally executed.
Figures, Tables including the legends should be placed at the end of the document OR in a separate file (not inserted into the main text).
a) PC compatible Adobe Illustrator AI files or .EPS files (for Mac users .eps)
as well as .PDF files if possible. TIF, BMP, GIF or .EPS are accepted if the resolution is 300 dpi for final published figure size. Files can be compressed with WinZip. JPG files are accepted in high quality compression only.
b) Excel and PowerPoint files are accepted (PC compatible) as separate attachments.
GALLEY PROOFS
Before publication the correspondent author will receive a copy of the final version of the paper, which should be read carefully for errors and returned promptly. Proofs will be sent for the correction of typographic errors only. No other changes will be accepted. Proofs not returned within 7 days will be considered as approved by the author(s).
LETTERS TO THE EDITOR
The Neuroendocrinology Letters has a section carrying comments, questions, or criticism about articles that have been published and where the original authors can respond. This section takes the form of Letters to the Editor, where also other topics and views from readers may be published and discussed.
SUPPLEMENTS / SUPPELEMENTAL ISSUES
Monographs or series of articles that have undergone regular scientific review, university approved theses, conference proceedings, symposia on related issues or topics, etc. may be printed as supplements to the Neuroendocrinology Letters. Supplements are published as a separate issue of the Journal and are negotiated in advance with the Editor-in-Chief.
COMMERCIAL REPRINTS – PDF FOR COMMERCIAL USE
Instead of Reprints, a print-quality PDF for commercial use can be ordered from the publisher.